Biomimetic Multimodal Evaluation Reveals Enhanced Efficacy and Safety of Cyclosporine A Nanomicelles (CycloNex) for Advanced Dry Eye Management
Source abstract
Abstract
ABSTRACT Dry eye disease (DED), which affects over 30% of the global population, demands advanced therapeutic strategies to overcome ocular bioavailability challenges. We developed nanomicelles (RH40‐P188/RH40‐P407, CycloNex) for enhanced cyclosporine A (CsA) delivery through innovative biological validation platforms. The 15‐nm micelles demonstrated exceptional stability (3 months at 25°C) and deep tissue penetration (50 µm in 3D corneal spheroids), outperforming Cequa by 2.3‐fold in ex vivo rabbit corneal accumulation. A breakthrough microfluidic‐integrated 3D total corneal model revealed 82% prolonged ocular retention vs. Cequa, while our hyperosmotic cell platform showed 55% greater reactive oxygen species reduction and 44% lower TNF‐α expression. In vivo studies confirmed NM P188 ‐CsA's superior bioavailability, and corneal repair was completed within 14 days in mice with benzalkonium chloride‐induced dry eye. These findings, validated through six complementary biological models—including HET‐CAM irritation scoring (0.89 vs. Cequa's 1.34)—establish a new paradigm for ocular nanotherapeutic evaluation while demonstrating clinically translatable advantages over current standards.
Source: crossref · Quality: baseline
Research context
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics School of Pharmaceutical Sciences Hebei Medical University Shijiazhuang People's Republic of China
Department of Ophthalmology Fourth Hospital of Hebei Medical University Shijiazhuang People's Republic of China
State Key Laboratory of New Pharmaceutical Preparations and Excipients Hebei Medical University Shijiazhuang People's Republic of China
Funding
National Natural Science Foundation of China
References (59)
Show source-provided references
1. Engineering Ultra‐Small Cerium‐Based Metal–Organic Frameworks Nanozymes for Efficient Antioxidative Treatment of Dry Eye Disease10.1002/adfm.202307569 ↗
2. 10.1016/j.bios.2023.11593310.1016/j.bios.2023.115933 ↗
3. 10.1002/advs.20200369910.1002/advs.202003699 ↗
4. 10.1007/s40265‐024‐02031‐610.1007/s40265‐024‐02031‐6 ↗
5. 10.1007/s40820‐024‐01322‐710.1007/s40820‐024‐01322‐7 ↗
6. 10.1002/advs.20241117210.1002/advs.202411172 ↗
7. 10.1016/j.nantod.2024.10235910.1016/j.nantod.2024.102359 ↗
8. 10.1097/icu.000000000000096810.1097/icu.0000000000000968 ↗
9. 10.1002/advs.20240956210.1002/advs.202409562 ↗
10. 10.1002/adma.20241535310.1002/adma.202415353 ↗
11. Nanotechnology Based Drug Delivery Systems for the Treatment of Anterior Segment Eye Diseases10.1016/j.jconrel.2023.01.018 ↗
12. Development and Evaluation of Cyclosporine a Mixed Micelle Eye Drops for Enhanced Ocular Drug Delivery10.1208/s12249-025-03129-0 ↗
13. 10.1186/s12951‐023‐01992‐210.1186/s12951‐023‐01992‐2 ↗
14. 10.2147/IJN.S55555510.2147/IJN.S555555 ↗
15. 10.3390/ma1415429010.3390/ma14154290 ↗
16. 10.3390/pharmaceutics1001002810.3390/pharmaceutics10010028 ↗
17. 10.1016/j.jconrel.2023.01.01810.1016/j.jconrel.2023.01.018 ↗
18. 10.1021/acs.molpharmaceut.7b0093910.1021/acs.molpharmaceut.7b00939 ↗
19. 10.3390/pharmaceutics1302019210.3390/pharmaceutics13020192 ↗
20. 10.1016/j.ijpharm.2024.12483710.1016/j.ijpharm.2024.124837 ↗
21. 10.1016/j.carbpol.2022.12000710.1016/j.carbpol.2022.120007 ↗
22. 10.1186/s13046‐019‐1107‐110.1186/s13046‐019‐1107‐1 ↗
23. 10.1021/acsami.4c0403910.1021/acsami.4c04039 ↗
24. 10.1016/j.tiv.2019.10466610.1016/j.tiv.2019.104666 ↗
25. 10.1016/j.ejpb.2023.05.00510.1016/j.ejpb.2023.05.005 ↗
26. 10.1021/acsnano.3c1151410.1021/acsnano.3c11514 ↗
27. Eye‐Drop Nano‐Formulation of Catalase Self‐Assembled with Thiolated Chitosan for Effective Treatment of Dry Eye Disease10.1002/adma.202415353 ↗
28. Cyclosporine A Nanosuspensions for Ophthalmic Delivery: a Comparative Study between Cationic Nanoparticles and Drug‐Core Mucus Penetrating Nanoparticles10.1021/acs.molpharmaceut.1c00370 ↗
29. Preparation of Curcumin Self‐Micelle Solid Dispersion with Enhanced Bioavailability and Cytotoxic Activity by Mechanochemistry10.1080/10717544.2017.1422298 ↗
30. Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes10.1021/jm970530e ↗
31. Hyaluronan‐Coated Nanoparticles for Active Tumor Targeting: Influence of Polysaccharide Molecular Weight on Cell Uptake10.1016/j.colsurfb.2021.112240 ↗
32. Therapeutic Strategies of Three‐Dimensional Stem Cell Spheroids and Organoids for Tissue Repair and Regeneration10.1016/j.bioactmat.2022.03.039 ↗
33. Liposome‐Based Permeable Eyedrops for Effective Posterior Segment Drug Delivery10.1002/adfm.202403142 ↗
34. Semifluorinated Alkane Based Systems for Enhanced Corneal Penetration of Poorly Soluble Drugs10.1016/j.ijpharm.2018.01.019 ↗
35. 10.3390/polym1409163510.3390/polym14091635 ↗
36. 10.1016/j.ijpharm.2019.05.01810.1016/j.ijpharm.2019.05.018 ↗
37. 10.3390/ijms2316915810.3390/ijms23169158 ↗
38. 10.1016/j.jconrel.2019.10.03910.1016/j.jconrel.2019.10.039 ↗
39. 10.1126/sciadv.adv166110.1126/sciadv.adv1661 ↗
40. 10.3390/nu1003028210.3390/nu10030282 ↗
41. 10.1371/journal.pone.022480510.1371/journal.pone.0224805 ↗
42. 10.1080/10717544.2018.145892310.1080/10717544.2018.1458923 ↗
43. 10.3390/pharmaceutics1002005710.3390/pharmaceutics10020057 ↗
44. 10.1016/j.colsurfb.2022.11302610.1016/j.colsurfb.2022.113026 ↗
45. 10.1016/j.ijpharm.2012.04.06010.1016/j.ijpharm.2012.04.060 ↗
46. 10.1021/acsami.3c1806110.1021/acsami.3c18061 ↗
47. 10.3390/pharmaceutics1208070210.3390/pharmaceutics12080702 ↗
48. Engineered Commensals for Targeted Nose‐to‐Brain Drug Delivery10.1016/j.cell.2025.01.017 ↗
49. In Vitro and Ex Vivo Models for Assessing Drug Permeation across the Cornea10.1021/acs.molpharmaceut.3c00195 ↗
50. Tear Dynamics and Dry Eye10.1016/S1350-9462(98)00004-4 ↗
51. In Vitro and Ex Vivo Corneal Penetration and Absorption Models10.1007/s13346-015-0275-6 ↗
52. Alleviation of Dry Eye Syndrome with One Dose of Antioxidant, Anti‐Inflammatory, and Mucoadhesive Lysine‐Carbonized Nanogels10.1016/j.actbio.2022.01.044 ↗
53. RETRACTED: Chitosan‐poly(lactide‐co‐glycolide)/Poloxamer Mixed Micelles as a Mucoadhesive Thermo‐Responsive Moxifloxacin Eye Drop to Improve Treatment Efficacy in Bacterial Keratitis10.1016/j.carbpol.2023.120822 ↗
54. N‐Acetylcysteine Functionalized Chitosan Oligosaccharide‐Palmitic Acid Conjugate Enhances Ophthalmic Delivery of Flurbiprofen and Its Mechanisms10.1016/j.carbpol.2022.119552 ↗
55. Mucosal Applications of Poloxamer 407‐Based Hydrogels: an Overview10.3390/pharmaceutics10030159 ↗
56. 10.1021/acsnano.3c0886910.1021/acsnano.3c08869 ↗
57. 10.1371/journal.pone.027059910.1371/journal.pone.0270599 ↗
58. 10.1021/acsnano.4c0042310.1021/acsnano.4c00423 ↗
59. 10.3389/fmed.2022.82759410.3389/fmed.2022.827594 ↗